GSK unites with 23andMe amid R&D revamp
27-07-2018
Willy Barton / Shutterstock.com
British-based pharmaceutical company GSK has entered into a five-year collaboration with the University of California to explore how gene mutations cause disease and accelerate drug discovery.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GSK, CRISPR, University of California, Jennifer Doudna, gene-editing, genetics, drug discovery
